cabazitaxel-loaded mixed polymeric micelle (MPB-1734) / MegaPro Biomedical - LARVOL DELTA

Preclinical studies of the cabazitaxel nanoformulation MPB-1734 support therapeutic application in chemo-resistant solid tumors and synergistic benefit in combination with immune checkpoint inhibitor (AACR 2023) - P1/2 | "However, with the high systemic toxicity such as neutropenia and hypersensitivity, the clinical use is restricted to patients with metastatic castration-resistant prostate cancer who show progression after docetaxel-based chemotherapy... MPB-1734 can reduce the major dose-limiting side effect (neutropenia) of CBZ and increase the tolerated dose. With tumor targeting ability, superior antitumor effects were demonstrated as compared with commercial formulation in a range of cancer models. MPB-1734 combined with anti-PD-1 antibody showed synergistic benefit in tumor inhibition."

Checkpoint inhibition • Combination therapy • Preclinical • Breast Cancer • Cervical Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • CD8

Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=81 | Recruiting | Sponsor: MegaPro Biomedical Co. Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Enrollment open • Trial completion date • Trial primary completion date • Oncology • Solid Tumor